Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP380620.RAa7j0Tx-VPRdJZZbx6vze3y1bPlmxF7q1GNUA5kvj2X8130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP380620.RAa7j0Tx-VPRdJZZbx6vze3y1bPlmxF7q1GNUA5kvj2X8130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP380620.RAa7j0Tx-VPRdJZZbx6vze3y1bPlmxF7q1GNUA5kvj2X8130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP380620.RAa7j0Tx-VPRdJZZbx6vze3y1bPlmxF7q1GNUA5kvj2X8130_provenance.
- NP380620.RAa7j0Tx-VPRdJZZbx6vze3y1bPlmxF7q1GNUA5kvj2X8130_assertion description "[Therapeutic inhibitors of HER3 should be considered as part of multidrug combinations aimed at completely and rapidly disabling the HER2 network in HER2-overexpressing breast cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP380620.RAa7j0Tx-VPRdJZZbx6vze3y1bPlmxF7q1GNUA5kvj2X8130_provenance.
- NP380620.RAa7j0Tx-VPRdJZZbx6vze3y1bPlmxF7q1GNUA5kvj2X8130_assertion evidence source_evidence_literature NP380620.RAa7j0Tx-VPRdJZZbx6vze3y1bPlmxF7q1GNUA5kvj2X8130_provenance.
- NP380620.RAa7j0Tx-VPRdJZZbx6vze3y1bPlmxF7q1GNUA5kvj2X8130_assertion SIO_000772 23224399 NP380620.RAa7j0Tx-VPRdJZZbx6vze3y1bPlmxF7q1GNUA5kvj2X8130_provenance.
- NP380620.RAa7j0Tx-VPRdJZZbx6vze3y1bPlmxF7q1GNUA5kvj2X8130_assertion wasDerivedFrom befree-20150227 NP380620.RAa7j0Tx-VPRdJZZbx6vze3y1bPlmxF7q1GNUA5kvj2X8130_provenance.
- NP380620.RAa7j0Tx-VPRdJZZbx6vze3y1bPlmxF7q1GNUA5kvj2X8130_assertion wasGeneratedBy ECO_0000203 NP380620.RAa7j0Tx-VPRdJZZbx6vze3y1bPlmxF7q1GNUA5kvj2X8130_provenance.
- befree-20150227 importedOn "2015-02-27" NP380620.RAa7j0Tx-VPRdJZZbx6vze3y1bPlmxF7q1GNUA5kvj2X8130_provenance.